Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Double-Blind Relapse Prevention Study of Paliperidone Palmitate 3-Month Formulation in Schizophrenia
KCT0000544Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of paliperidone palmitate in schizophrenia, sponsored by Janssen Pharmaceutical. Started Aug 2012; status: completed.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on KCT0000544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0000544.